tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GRI Stock Latest News

GRI Bio reports six-week lung function data in Phase 2a study of GRI-0621
The FlyGRI Bio reports six-week lung function data in Phase 2a study of GRI-0621
19d ago
GRI
Gri Bio Reports Q2 Loss Amid Clinical Advancements
PremiumCompany Announcements
Gri Bio Reports Q2 Loss Amid Clinical Advancements
1M ago
GRI
GRI Bio Advances with Positive GRI-0621 Data
PremiumCompany Announcements
GRI Bio Advances with Positive GRI-0621 Data
1M ago
8K
GRI
GRI Bio Stockholders Approve Equity Plan Amendment
PremiumCompany Announcements
GRI Bio Stockholders Approve Equity Plan Amendment
2M ago
8K
GRI
Gri Bio, Inc. (GRI) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Gri Bio, Inc. (GRI) Q2 Earnings Cheat Sheet
2M ago
GRI
Buy Recommendation for GRI Bio: Promising Phase 2a Study of GRI-0621 in IPF with Strong Biomarker Strategy
PremiumRatingsBuy Recommendation for GRI Bio: Promising Phase 2a Study of GRI-0621 in IPF with Strong Biomarker Strategy
2M ago
GRI
GRI Bio Announces Positive Interim Data for GRI-0621
Premium
Company Announcements
GRI Bio Announces Positive Interim Data for GRI-0621
2M ago
8K
GRI
GRI Bio reports 6-week interim biomarker results from Phase 2a study in IPF
Premium
The Fly
GRI Bio reports 6-week interim biomarker results from Phase 2a study in IPF
2M ago
GRI
Optimistic Buy Rating for GRI Bio Amidst Promising Clinical Trial Developments and Strategic Insights
PremiumRatings
Optimistic Buy Rating for GRI Bio Amidst Promising Clinical Trial Developments and Strategic Insights
3M ago
GRI
GRI Bio completes enrollment in Phase 2a study of GRI-0621
PremiumThe Fly
GRI Bio completes enrollment in Phase 2a study of GRI-0621
3M ago
GRI
GRI Bio Announces Positive Interim Phase 2a Results
PremiumCompany Announcements
GRI Bio Announces Positive Interim Phase 2a Results
3M ago
8K
GRI
GRI Bio reports 6-week interim safety data from Phase 2a study of GRI-0621
PremiumThe Fly
GRI Bio reports 6-week interim safety data from Phase 2a study of GRI-0621
3M ago
GRI
Optimistic Buy Rating for GRI Bio Driven by Promising Clinical Developments and Safety Profile
PremiumRatingsOptimistic Buy Rating for GRI Bio Driven by Promising Clinical Developments and Safety Profile
4M ago
GRI
GRI Bio Expands Share Offering Agreement
Premium
Company Announcements
GRI Bio Expands Share Offering Agreement
4M ago
8K
GRI
GRI Bio presents preclinical data on GRI-0621
Premium
The Fly
GRI Bio presents preclinical data on GRI-0621
4M ago
GRI
GRI Bio Advances in IPF Treatment with Promising Trial Results
PremiumCompany Announcements
GRI Bio Advances in IPF Treatment with Promising Trial Results
4M ago
GRI
GRI Bio expects cash to fund operations through Q3 of 2025
PremiumThe Fly
GRI Bio expects cash to fund operations through Q3 of 2025
5M ago
GRI
GRI Bio reports interim biomarker data from Phase 2a study of GRI-0621
PremiumThe Fly
GRI Bio reports interim biomarker data from Phase 2a study of GRI-0621
5M ago
GRI
GRI Bio announces enrollment update for Phase 2a study of GRI-0621
PremiumThe Fly
GRI Bio announces enrollment update for Phase 2a study of GRI-0621
5M ago
GRI
Promising Prospects for GRI Bio: Matthew Keller’s Buy Rating on GRI-0621 Amid Positive Phase 2a Safety Data
PremiumRatingsPromising Prospects for GRI Bio: Matthew Keller’s Buy Rating on GRI-0621 Amid Positive Phase 2a Safety Data
6M ago
GRI
GRI Bio reports interim 2-week safety results from Phase 2a study of GRI-0621
Premium
The Fly
GRI Bio reports interim 2-week safety results from Phase 2a study of GRI-0621
6M ago
GRI
GRI Bio announces the granting of two global patents for Europe, Japan
Premium
The Fly
GRI Bio announces the granting of two global patents for Europe, Japan
6M ago
GRI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >